Mark wants a more convenient treatment option
Mark is 52 years old, and lives with his wife and two teenage daughters.* He is a structural engineer, and enjoys spending time with his family.
Diagnosis and treatment history
Mark was diagnosed with acromegaly six years ago, after he experienced severe vision loss. Mark had surgery to reduce a tumor impinging on the optic nerve, and then started taking Sandostatin® short-acting injection. After two weeks of Sandostatin® Injection 50 mcg t.i.d., Mark switched to Sandostatin LAR® Depot 20 mg IM intragluteally at 4-week intervals.
Mark at the moment
Although his symptoms are controlled, Mark is not completely satisfied. Balancing work, family, and monthly appointments for injections is a hassle, especially if the Sandostatin LAR® Depot is not mixed properly. When that happens, Mark has to pick up a new prescription, make another appointment, and fill out extra paperwork to get reimbursed.
Mark wants to try something more convenient and Somatuline® Depot (lanreotide) Injection (lanreotide) Injection offers the ease of a pre-mixed solution in a single, pre-filled syringe.
Do any of your patients resemble Mark?
Last year Somatuline® Depot (lanreotide) Injection helped over 6000 patients with acromegaly,2 including three fictional, but typical, patients named Mark (above), Dave, and Karen (below). See if your patients are like:
* Mark is not an actual patient. His profile is based on published data from clinical studies and review articles.
Indication and Important Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.
There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.
A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).
For Full Prescribing Information, click here.
